Nervous System (e.g., Central Nervous System (cns), Etc.) Affecting Patents (Class 514/17.7)
Alzheimer's disease (Class 514/17.8)
Multiple sclerosis (Class 514/17.9)
Neurotransmitter or derivative affecting or utilizing (Class 514/18.1)
Neuropathy affecting (Class 514/18.2)
Pain affecting (Class 514/18.3)
  • Neuregulin variants and methods of screening and using thereof
    Patent number: 8476405
    Abstract: The present invention provides polypeptide variants of neuregulin-1? (NRG-1?) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1? and methods of using polypeptide variants of NRG-1? for treating diseases.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: July 2, 2013
    Assignee: Zensun (Shanghai) Science & Technology Ltd.
    Inventor: Mingdong Zhou
  • AUGMENTED COGNITIVE TRAINING
    Publication number: 20130164721
    Abstract: The present invention provides methods of therapy of cognitive deficits associated with a central nervous system disorder or condition, methods of enhancing cognitive performance and methods for repeated stimulation of neuronal activity or a pattern of neuronal activity, such as that underlying a specific neuronal circuit(s). The methods comprise combining cognitive training protocols and a general administration of CREB pathway-enhancing agents.
    Type: Application
    Filed: February 19, 2013
    Publication date: June 27, 2013
    Applicant: COLD SPRING HARBOR LABORATORY
    Inventor: Cold Spring Harbor Laboratory
  • QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS
    Publication number: 20130165386
    Abstract: Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).
    Type: Application
    Filed: August 31, 2011
    Publication date: June 27, 2013
    Applicant: HANMI SCIENCE CO., LTD
    Inventors: In Hwan Bae, Eun Young Byun, Hae Kyoung Ju, Ji Young Song, Seung Hyun Jung, Seung Ah Jun, Ho Seok Kim, Young Hee Jung, Mi Yon Shim, Young Gil Ahn, Maeng Sup Kim
  • NEUROGENIN
    Publication number: 20130165385
    Abstract: The invention relates to novel neurogenin proteins, nucleic acids and antibodies.
    Type: Application
    Filed: June 26, 2012
    Publication date: June 27, 2013
    Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: David J. Anderson, Qiufu Ma, Lukas Sommer
  • Catecholamine regulated protein
    Patent number: 8470779
    Abstract: A novel mammalian catecholamine-regulated protein called CRP40 is identified. This protein, and nucleic acid encoding same, is useful in methods of diagnosing and treating hypodopaminergic neurological disease, such as Parkinson's disease, multisystem atrophy, lewy body dementia, schizophrenia, and bipolar disease.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: June 25, 2013
    Assignee: CRP40 Inc.
    Inventors: Joseph Gabriele, Ram Mishra, Zdenek Pristupa
  • THERAPY FOR SUBARACHNOID HEMORRHAGE AND ISCHEMIA
    Publication number: 20130156704
    Abstract: The application provides data from a clinical trial of a PSD-95 inhibitor in subjects undergoing endovascular repair of an aneurysm in or otherwise affecting the CNS. The subjects were stratified by whether the aneurysm ruptured before performing the endovascular surgery. Rupture is associated with higher mortality or increased debilitation if a subject survives. The trial provided evidence of significant benefit in subjects with and without aneurysm rupture before endovascular was surgery performed. Surprisingly, the subjects benefiting most from treatment as judged both by pathology and neurocognitive outcome were those in which the aneurysm had ruptured causing a subarachnoid hemorrhage. These data constitute evidence that a PSD-95 inhibitor is beneficial not only in ischemic and hemorrhagic stroke but in forms of hemorrhage in or affecting the CNS, particularly, subarachnoid hemorrhage.
    Type: Application
    Filed: February 22, 2013
    Publication date: June 20, 2013
    Applicant: NoNO Inc.
    Inventor: NoNO Inc.
  • NOCICEPTIN MIMETICS
    Publication number: 20130157928
    Abstract: The present invention relates to nociceptin peptide mimetics that have ?-helical structures and bind to and modulate the opioid receptor-like-1 (ORL-1) receptor. The peptide mimetics are constrained cyclic nociceptin analogues which have either agonist or antagonist activity. Pharmaceutical compositions comprising the nociceptin peptide mimetics and methods of treating or preventing a disease or condition ameliorated by modulating the ORL-1 receptor are also described.
    Type: Application
    Filed: June 7, 2011
    Publication date: June 20, 2013
    Inventors: David Fairlie, Rosemary Sharon Harrison, Nicholas Evan Shepherd
  • ISOLATED PROTEIN MEDICAMENT
    Publication number: 20130156697
    Abstract: The invention in suitable embodiments is directed to an isolated protein comprising one or more amino acid sequences, each amino acid sequence capable of being functionalized and/or attached in whole and/or in part to one or more or a plurality of elements of one or more types including to cargo elements, forming a composition of elements suitable for use as an in vivo and/or in vitro medicament to treat one or more biological species.
    Type: Application
    Filed: December 21, 2012
    Publication date: June 20, 2013
    Inventors: FRANCO VITALIANO, GORDANA DRAGAN VITALIANO
  • Biomarkers for the diagnosis of ALS
    Patent number: 8465727
    Abstract: Methods for determining the onset of ALS in a subject are provided. One method includes analyzing a sample obtained from the subject for the presence or amount of one or more biomarkers indicative of ALS. In a preferred embodiment, the biomarkers are one or more of the following: C-reactive protein (CRP), cystatin c, plasminogen, complement C3, CysGly-transthyretin, and phosphorylated neurofilament heavy chain (pNFH). The sample is typically cerebral spinal fluid (CSF). The levels or concentrations of the biomarkers can be used to determine the onset of ALS, monitor the progression of ALS, or monitor the progression of a treatment for ALS.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: June 18, 2013
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Robert P. Bowser
  • RECOMBINANT PROTEIN FOR INTRACELLULAR DELIVERY OF siRNA AND COMPOSITION COMPRISING THE SAME
    Publication number: 20130150287
    Abstract: The present invention relates to a recombinant protein for siRNA delivery, which allows the efficient intracellular and in vivo delivery of siRNA. More particularly, the present invention relates to a recombinant protein that allows a siRNA binding protein to be located in the interior cavity of a capsid protein of HBV (Hepatitis B virus), in which siRNAs of interest bind to the siRNA binding protein to be encapsulated within the capsid shell, thereby providing stability against the external attack such as nucleases and achieving the efficient intracellular and in vivo delivery of siRNA by its release into the cytosolic space after cell uptake.
    Type: Application
    Filed: December 7, 2011
    Publication date: June 13, 2013
    Applicant: Korea Institute of Science and Technology
    Inventors: Hyung-Jun AHN, Ick-Chan Kwon, Kui-Won Choi
  • Crystalline Peptide Epoxy Ketone Protease Inhibitors and the Synthesis of Amino Acid Keto-Epoxides
    Publication number: 20130150289
    Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides.
    Type: Application
    Filed: February 1, 2013
    Publication date: June 13, 2013
    Applicant: Onyx Therapeutics, Inc.
    Inventor: Onyx Therapeutics, Inc.
  • PEG BASED HYDROGEL FOR PERIPHERAL NERVE INJURY APPLICATIONS AND COMPOSITIONS AND METHOD OF USE OF SYNTHETIC HYDROGEL SEALANTS
    Publication number: 20130142781
    Abstract: Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.
    Type: Application
    Filed: December 3, 2012
    Publication date: June 6, 2013
    Applicant: INVIVO THERAPEUTICS CORPORATION
    Inventor: InVivo Therapeutics Corporation
  • Use of CHEC Peptides to Treat Neurological and Cardiovascular Diseases and Disorders
    Publication number: 20130143792
    Abstract: The present invention describes compositions and methods for treating and preventing non-degenerative neurological diseases and disorders associated with elevated sPLA2 activity as well as cardiovascular diseases using a CHEC peptide to inhibit sPLA2 activity.
    Type: Application
    Filed: March 28, 2011
    Publication date: June 6, 2013
    Applicant: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
    Inventor: Timothy J. Cunningham
  • METHOD OF TREATMENT OF HIV OR AIDS
    Publication number: 20130143795
    Abstract: The invention relates to a method of treating HIV or AIDS comprising administering a composition comprising a polypeptide comprising LKKTETQ (SEQ ID NO: 1) or a variant thereof, or administering a composition comprising a peptidomimetic of a polypeptide comprising amino acid sequence LKKTETQ (SEQ ID NO: 1) or a variant thereof.
    Type: Application
    Filed: July 14, 2011
    Publication date: June 6, 2013
    Applicant: Adistem Ltd.
    Inventor: Vasilis Paspaliaris
  • Method for enhancing skin appearance
    Patent number: 8454975
    Abstract: A method for treating skin by administration of a neurotoxin such as a botulinum toxin by means of a dry needle. The method can be used to accomplish what has generally been described as skin rejuvenation and also to treat skin disorders such as skin lines, crepiness, excess skin, wrinkles, platysmal bands, uneven skin tone and color, and hyperhidrosis.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: June 4, 2013
    Inventor: Elizabeth VanderVeer
  • Dimeric Oxidation-Resistant Apolipoprotein A1 Variants
    Publication number: 20130137628
    Abstract: An isolated oxidation-resistant ApoA1 variant dimer includes a first oxidation-resistant ApoA1 variant polypeptide monomer and a second oxidation-resistant ApoA1 variant polypeptide monomer, wherein at least one of the first and the second monomers comprises at least one amino acid substitution of a tryptophan residue for an oxidation resistant amino acid, or a functional fragment or variant thereof. Methods for treating a disease or disorder comprises administering to a subject in need thereof, a therapeutically effective amount of an isolated oxidation-resistant ApoA1 variant dimer, an oxidation-resistant ApoA1 variant monomer, an oxidation-resistant ApoA1 monomer-lipid complex, a lipid complexed oxidation-resistant ApoA1 variant monomer, a lipid complexed oxidation-resistant ApoA1 variant dimer, or combinations thereof to the subject to enhance cholesterol efflux activity in the presence of an oxidant.
    Type: Application
    Filed: May 11, 2011
    Publication date: May 30, 2013
    Applicant: ESPERION THERAPEUTICS, INC.
    Inventors: Roger S. Newton, Rai Ajit K. Srivastava, Timothy R. Hurley, Clay Cramer, Sergey V. Filippov, Stephen L. Pinkosky
  • Methods for reducing botulinum neurotoxin A toxicity
    Patent number: 8450277
    Abstract: The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: May 28, 2013
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Edwin R. Chapman, Min Dong
  • LIPOSOMAL FORMULATION FOR ORAL ADMINISTRATION OF GLUTATHIONE (REDUCED) VIA GEL CAPSULE
    Publication number: 20130129815
    Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.
    Type: Application
    Filed: December 31, 2012
    Publication date: May 23, 2013
    Applicants: YOUR ENERGY SYSTEMS, LLC
    Inventors: Your Energy Systems, LLC, Frederick Timothy Guilford, Brian C. Keller
  • NEUROPROTECTION BY HEPATIC CELLS AND HEPATOCYTE SECRETORY FACTORS
    Publication number: 20130130982
    Abstract: The present invention relates to compositions and methods for neuroprotection. In particular, provided herein are compositions (e.g., hepatocyte secretory factors) for alleviating and/or protecting against neuronal damage (e.g., resulting from stroke), and methods of use thereof.
    Type: Application
    Filed: May 3, 2012
    Publication date: May 23, 2013
    Inventor: Shu Q. Liu
  • SELF-RENEWAL PROMOTER FOR NEURAL STEM CELLS AND METHOD FOR USING SAME
    Publication number: 20130129708
    Abstract: An object of the present invention to provide an agent for promoting the self-renewal of the neural stem cells and a method of using the same. ECF-L contained in a culture supernatant of endothelial progenitor cells derived from bone marrow has an effect of promoting the self-renewal of neural stem cells. Accordingly, ECF-L can be used as an ingredient of an agent for promoting the self-renewal of the neural stem cells, a pharmaceutical composition for growing the neural stem cells, and a pharmaceutical composition for treating a disease associated with neural dysfunction.
    Type: Application
    Filed: April 26, 2011
    Publication date: May 23, 2013
    Inventors: Jun Namiki, Hideyuki Okano
  • NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS
    Publication number: 20130123186
    Abstract: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.
    Type: Application
    Filed: October 30, 2012
    Publication date: May 16, 2013
    Applicants: Allon Therapeutics Inc., Ramot at Tel-Aviv University Ltd.
    Inventors: Illana Gozes, Alistair Stewart, Maya Maor, Sharon Furman-Assaf
  • PEPTIDES FOR THE REGULATION OF NEUROTRANSMITTER SEQUESTRATION AND RELEASE
    Publication number: 20130123187
    Abstract: A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises: (a) introducing a plurality of agents into a plurality of cells; and (b) analyzing Vesicular Monoamine Transporter 2 (VMAT2) transcription in the cells; and (c) identifying an agent of the plurality of agents capable of up-regulating DJ-1-dependent VMAT2 transcription in the cells, thereby selecting the agent comprising the neuroprotecting activity.
    Type: Application
    Filed: October 29, 2012
    Publication date: May 16, 2013
    Applicant: Ramot at Tel-Aviv University Ltd.
    Inventor: Ramot at Tel-Aviv University Ltd.
  • Osteoprotegerin in Neuroprotection
    Publication number: 20130122017
    Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.
    Type: Application
    Filed: November 8, 2012
    Publication date: May 16, 2013
    Applicant: MASSACHUSETTS EYE AND EAR INFIRMARY
    Inventor: MASSACHUSETTS EYE AND EAR INFIRMARY
  • Pharmaceutical and/or cosmetic composition containing active-principle activators of aconitase
    Patent number: 8440615
    Abstract: A cosmetic or pharmaceutical composition, and in particular a dermatological one, including, in a physiologically adapted medium, active principles capable of activating aconitase, and methods of using the composition for protection of mitochondria, the skin and the appendages from external aggressions and to combat cutaneous aging. These active principles may be composed of polypeptides or of peptides, used alone or in association with at least one other active principle.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: May 14, 2013
    Assignee: Societe d'Extraction des Principes Actifs (Vincience)
    Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
  • Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
    Patent number: 8440621
    Abstract: Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore and such fluorophore-tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: May 14, 2013
    Assignees: The Regents of the University of California, Bachem Biosciences, Inc.
    Inventors: George K. Chandy, Christine Beeton, Michael William Pennington
  • GM1-LIKE PEPTIDES AND USES THEREOF
    Publication number: 20130115170
    Abstract: Compositions and methods relating to interfering with the interaction of gangliosides, such as GM1, with their ligands are provided. For example, methods are provided for treating infections by blocking the infectious agent from binding with GM1 using GM1-like peptides. Also provided are methods of inhibiting ligands from binding to GM 1 on the surface of cells and for neutralizing anti-GM1 antibodies in neurological diseases.
    Type: Application
    Filed: October 19, 2012
    Publication date: May 9, 2013
    Inventors: Robert Yu, Han-Chung Wu, Seigo Usuki
  • TRANSPORT PROTEIN WHICH IS USED TO INTRODUCE CHEMICAL COMPOUNDS INTO NERVE CELLS
    Publication number: 20130116191
    Abstract: The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.
    Type: Application
    Filed: September 10, 2012
    Publication date: May 9, 2013
    Applicant: TOXOGEN GMBH
    Inventor: Andreas Rummel
  • Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
    Patent number: 8435523
    Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.
    Type: Grant
    Filed: May 4, 2010
    Date of Patent: May 7, 2013
    Assignee: Abbott Research B.V.
    Inventors: John Powell, Duncan Casson, Mark Maginn, Wei Liu, Sandeep Dutta, Andrea Best, Jerry A. Hall
  • Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
    Patent number: 8435949
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: May 7, 2013
    Assignee: Stem Cell Therapeutics Corp.
    Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg
  • Methods and compositions related to improving properties of pharmacological agents targeting nervous system
    Patent number: 8435940
    Abstract: Disclosed are compositions and methods related to improving pharmacological properties of bioactive compounds targeting nervous system.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: May 7, 2013
    Assignee: University of Utah Research Foundation
    Inventors: Grzegorz Bulaj, H. Steve White
  • METHODS AND USES OF NUR77 AND NUR77 AGONISTS TO MODULATE MACROPHAGES AND MONOCYTES, AND TREAT INFLAMMATION, INFLAMMATORY DISEASE AND CARDIOVASCULAR DISEASE
    Publication number: 20130108602
    Abstract: Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject; decreasing, reducing, inhibiting, suppressing, limiting or controlling an autoimmune response, disorder or disease in a subject; and decreasing, reducing, inhibiting, suppressing, limiting or controlling an adverse cardiovascular event or cardiovascular disease in a subject, are provided. Methods include, for example, administering a Nur77 polypeptide or subsequence thereof, a Nur77 agonist, or CD14+ CD16+ monocytes or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes or macrophages to a subject to decrease, reduce, inhibit, suppress, limit or control the underlying condition or an adverse symptom or pathology of the condition.
    Type: Application
    Filed: October 5, 2012
    Publication date: May 2, 2013
    Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventor: LA JOLLA INSTITUTE FOR ALLERGY AND IMMU
  • METHODS FOR INHIBITING NECROSIS
    Publication number: 20130109615
    Abstract: A method of treating a patient suffering from a disease characterized by tissue necrosis by administering to the patient a necrosis inhibitor and/or a Humanin or a derivative of Humanin is provided. The invention further includes a method for prophylactically treating a patient at risk for a pathological condition that is precipitated at least in part by tissue necrosis by administering to the patient a necrosis inhibitor and/or a Humanin or a derivative of Humanin.
    Type: Application
    Filed: February 23, 2011
    Publication date: May 2, 2013
    Applicant: Ben Gurion University of the Negev Research and Development Authority
    Inventors: Abraham Parola, Ilana Nathan, Ron Kasher, Jenny Lerner Yardeni, Aviv Cohen
  • COMPOSITIONS FOR OXYGEN TRANSPORT COMPRISING A HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN
    Publication number: 20130102521
    Abstract: The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics.
    Type: Application
    Filed: December 14, 2012
    Publication date: April 25, 2013
    Applicant: SANGART, INC.
    Inventor: Sangart, Inc.
  • INHIBITORS OF PROTEIN KINASES AND USES THEREOF
    Publication number: 20130102522
    Abstract: Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders.
    Type: Application
    Filed: March 15, 2012
    Publication date: April 25, 2013
    Applicant: PHARMAGAP INC.
    Inventors: Raphael Terreux, Jenny Phipps
  • USE OF DES-ASPARTATE-ANGIOTENSIN I IN INFLAMMATION-RELATED PATHOLOGIES AND DISEASES
    Publication number: 20130095082
    Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.
    Type: Application
    Filed: June 8, 2011
    Publication date: April 18, 2013
    Inventor: Meng Kwoon Sim
  • NEUBLASTIN VARIANTS
    Publication number: 20130096065
    Abstract: Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal.
    Type: Application
    Filed: July 3, 2012
    Publication date: April 18, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Anthony Rossomando, Laura Silvian, R. Blake Pepinsky
  • TREATING NEUROLOGICAL DISORDERS
    Publication number: 20130095175
    Abstract: Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.
    Type: Application
    Filed: December 18, 2012
    Publication date: April 18, 2013
    Applicant: BIOGEN IDEC MA INC.
    Inventor: Biogen Idec Ma Inc.
  • Therapeutic use of IgG as a neuroprotective agent
    Patent number: 8414888
    Abstract: The present invention relates to compositions containing IgG and methods for the promotion of nerve regeneration or prevention or inhibition of neuronal degeneration by IgG to ameliorate the effects of injury, disorder or disease of the nervous system.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: April 9, 2013
    Assignee: University Health Network
    Inventors: Michael Fehlings, Sherri Robins
  • Administration of growth factors for the treatment of CNS disorders
    Patent number: 8409548
    Abstract: A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: April 2, 2013
    Assignee: The Regents of the University of California
    Inventor: Krystof S. Bankiewicz
  • Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
    Patent number: 8409584
    Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: April 2, 2013
    Assignee: New York University
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • MUTEINS OF HUMAN LIPOCALIN 2 (LCNC,HNGAL) WITH AFFINITY FOR A GIVEN TARGET
    Publication number: 20130079286
    Abstract: The present invention relates to a novel library for the generation of muteins and to novel muteins derived from human lipocalin 2 (Lcn2, hNGAL) and related proteins that bind a given target with detectable affinity. The invention also relates to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. For example, such muteins may serve to bind and deplete pathological forms of natural biomolecules such as the amyloid beta peptide in Alzheimer's disease or may target the fibronectin extra-domain B, which is associated with tumor neovasculature.
    Type: Application
    Filed: December 7, 2010
    Publication date: March 28, 2013
    Inventors: Arne Skerra, Michaela Gebauer, Dominik Hinz, Sabine Rauth, Gabriele Matschiner, Martin Huelsmeyer
  • Treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
    Patent number: 8404642
    Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: March 26, 2013
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
  • COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION
    Publication number: 20130072422
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: March 1, 2011
    Publication date: March 21, 2013
    Inventors: Kevin D. Shenk, Francesco Paralati, Mark K. Bennett
  • METHODS AND COMPOSITIONS FOR STABLE LIQUID DRUG FORMULATIONS
    Publication number: 20130071412
    Abstract: The invention features a powdered composition including a pharmaceutically active compound and a protein or a hydrolyzed protein. In particular, the powdered composition forms a stable solution or dispersion suitable for oral administration in which the protein or the hydrolyzed protein is bound to the pharmaceutically active compound. The invention also provides a method of administering the composition, such as to a patient with dysphasia; liquid or semi-solid formulations of the composition; methods for preparing the composition; and kits including the composition.
    Type: Application
    Filed: December 17, 2010
    Publication date: March 21, 2013
    Applicant: Exodos Life Sciences Limited Partnership
    Inventors: Harry J. Leighton, Crist J. Frangakis
  • NEUREGULIN ISOFORMS,NEUREGULIN POLYPEPTIDES AND USES THEREOF
    Publication number: 20130072437
    Abstract: The present invention relates to new therapeutic and diagnostic uses of soluble neuregulin-1 isoforms and polypeptides, particularly neurological disorders.
    Type: Application
    Filed: May 27, 2011
    Publication date: March 21, 2013
    Applicant: MIND-NRG SA
    Inventors: Thierry Baussant, Daniel Bach, André Schrattenholz
  • TREATMENT OF SIRTUIN (SIRT) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A SIRTUIN (SIRT)
    Publication number: 20130072421
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.
    Type: Application
    Filed: January 13, 2011
    Publication date: March 21, 2013
    Applicant: CURNA, INC
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
  • Methods of treating dementia using a GM-CSF antagonist
    Patent number: 8398972
    Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.
    Type: Grant
    Filed: February 11, 2010
    Date of Patent: March 19, 2013
    Assignee: KaloBios Pharmaceuticals, Inc.
    Inventors: Christopher R. Bebbington, Geoffrey T. Yarranton, Varghese Palath
  • ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE
    Publication number: 20130065816
    Abstract: This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.
    Type: Application
    Filed: November 2, 2010
    Publication date: March 14, 2013
    Applicant: The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, Jerome L. Maderdrut, Min Li
  • MODULATORS OF PROTEASOME ACTIVITY
    Publication number: 20130065834
    Abstract: Methods of modulating proteasome activity, increasing life span and neurogenesis are provided herein.
    Type: Application
    Filed: July 25, 2012
    Publication date: March 14, 2013
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: David Vilchez, Andrew Dillin
  • Crystalline Peptide Epoxyketone Immunoproteasome Inhibitor
    Publication number: 20130065827
    Abstract: The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions.
    Type: Application
    Filed: April 6, 2011
    Publication date: March 14, 2013
    Inventor: Pasit Phiasivongsa